It is interesting to note that while no sex-specific differences in clinical presentation have been reported in MLIV patients or MLIV mouse models (Y.G., unpublished observations), we have noticed some discrepancies in our male and female experimental cohorts in response to CPP16-MCOLN1 treatment. This evidence concerns the gene MCOLN1 and mucolipidosis type IV.